• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Laidlaw initiated coverage on Senti Bio with a new price target

    6/6/25 8:36:59 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SNTI alert in real time by email
    Laidlaw initiated coverage of Senti Bio with a rating of Buy and set a new price target of $5.00
    Get the next $SNTI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNTI

    DatePrice TargetRatingAnalyst
    6/6/2025$5.00Buy
    Laidlaw
    10/7/2022$7.50Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SNTI
    SEC Filings

    See more
    • Senti Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Senti Biosciences, Inc. (0001854270) (Filer)

      6/18/25 7:05:30 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Senti Biosciences Inc.

      SCHEDULE 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)

      5/15/25 4:43:33 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Senti Biosciences Inc.

      SCHEDULE 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)

      5/15/25 4:41:42 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SNTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Collins James J.

      4 - Senti Biosciences, Inc. (0001854270) (Issuer)

      6/27/25 7:55:15 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Hsiung Feng

      4 - Senti Biosciences, Inc. (0001854270) (Issuer)

      6/27/25 7:55:03 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Schulz Fran

      4 - Senti Biosciences, Inc. (0001854270) (Issuer)

      6/27/25 7:53:44 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care